



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: C12N 15/29, 15/82, A01N 65/00, C12Q 1/68, A01H 5/00	A1	(11) International Publication Number: WO 96/31608 (43) International Publication Date: 10 October 1996 (10.10.96)
(21) International Application Number: PCT/GB96/00849 (22) International Filing Date: 9 April 1996 (09.04.96) (30) Priority Data: 9507232.8 7 April 1995 (07.04.95) GB (71) Applicant (for all designated States except US): JOHN INNES CENTRE INNOVATIONS LIMITED [GB/GB]; Norwich Research Park, Colney Lane, Norwich NR4 7UH (GB). (72) Inventors; and (75) Inventors/Applicants (for US only): JONES, Jonathan, Dallas, George [GB/GB]; 19 Waverly Road, Norwich, Norfolk NR4 6SG (GB). PARKER, Jane [GB/GB]; 182 Earham Road, Norwich, Norfolk NR2 3RW (GB). COLEMAN, Mark [GB/GB]; 55 St. Phillips Road, Norwich, Norfolk NR2 3BN (GB). DANIELS, Michael, John [GB/GB]; 9 Mile End Road, Norwich, Norfolk NR4 7QY (GB). SZABO, Véronique [FR/US]; University of California, NSF Center for Engineering Plants for Resistance Against Pathogens (CEPRAP), 1930 Fifth Street, Davis, CA 95616 (US). (74) Agents: WALTON, Seán et al.; Mewburn Ellis, York House, 23 Kingsway, London WC2B 6HP (GB).		(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the</i> <i>claims and to be republished in the event of the receipt of</i> <i>amendments.</i>
(54) Title: PLANT PATHOGEN RESISTANCE GENES AND USES THEREOF (57) Abstract <p>The <i>Arabidopsis RPP5</i> gene has been cloned and its sequence provided, along with the encoded amino acid sequence. DNA encoding the polypeptide, and alleles, mutants and derivatives thereof, may be introduced into plant cells and the encoded polypeptide expressed, conferring pathogen resistance on plants comprising such cells and descendants thereof. The <i>RPP5</i> sequence comprises leucine rich repeats and the presence of such repeats enables identification of other plant pathogen resistance genes. Homologies between <i>RPP5</i> and other pathogen resistance genes reveal motifs useful in identification of other pathogen resistance genes.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

PLANT PATHOGEN RESISTANCE GENES AND USES THEREOF

The present invention relates to pathogen resistance in plants and more particularly to the identification and use of pathogen resistance genes.

5 It is based on cloning of the *Arabidopsis* *RPP5* gene.

Plants are constantly challenged by potentially pathogenic microorganisms. Crop plants are particularly vulnerable, because they are usually grown as genetically uniform monocultures; when
10 disease strikes, losses can be severe. However, most plants are resistant to most plant pathogens. To defend themselves, plants have evolved an array of both preexisting and inducible defences. Pathogens must specialize to circumvent the defence mechanisms
15 of the host, especially those biotrophic pathogens that derive their nutrition from an intimate association with living plant cells. If the pathogen can cause disease, the interaction is said to be compatible, but if the plant is resistant, the
20 interaction is said to be incompatible. Race specific resistance is strongly correlated with the hypersensitive response (HR), an induced response by which (it is hypothesized) the plant deprives the pathogen of living host cells by localized cell death
25 at sites of attempted pathogen ingress.

It has long been known that HR-associated disease resistance is often (though not exclusively) specified by dominant genes (*R* genes). Flor showed that when

pathogens mutate to overcome such R genes, these mutations are recessive. Flor concluded that for R genes to function, there must also be corresponding genes in the pathogen, denoted avirulence genes (Avr genes). To become virulent, pathogens must thus stop making a product that activates R gene-dependent defence mechanisms (Flor, 1971). A broadly accepted working hypothesis, often termed the elicitor/receptor model, is that R genes encode products that enable plants to detect the presence of pathogens, provided said pathogens carry the corresponding Avr gene (Gabriel and Rolfe, 1990). This recognition is then transduced into the activation of a defence response.

Some interactions exhibit different genetic properties. *Helminthosporium carbonum* races that express a toxin (Hc toxin) infect maize lines that lack the Hm1 resistance gene. Mutations to loss of Hc toxin expression are recessive, and correlated with loss of virulence, in contrast to gene-for-gene interactions in which mutations to virulence are recessive. A major accomplishment was reported in 1992, with the isolation by tagging of the *Hm1* gene. (Johal and Briggs, 1992). Plausible arguments have been made for how gene-for-gene interactions could evolve from toxin-dependent virulence. For example, plant genes whose products were the target of the toxin might mutate to confer even greater sensitivity

to the toxin, leading to HR, and the conversion of a sensitivity gene to a resistance gene. However, this does not seem to be the mode of action of *Hml*, whose gene product inactivates Hc toxin.

5 Pathogen avirulence genes are still poorly understood. Several bacterial Avr genes encode hydrophilic proteins with no homology to other classes of protein, while others carry repeating units whose number can be modified to change the range of plants
10 on which they exhibit avirulence (Keen, 1992; Long and Staskawicz, 1993). Additional bacterial genes (*hrp* genes) are required for bacterial Avr genes to induce HR, and also for pathogenicity (Keen, 1992; Long and Staskawicz, 1993). It is not clear why pathogens make
15 products that enable the plant to detect them. It is widely believed that certain easily discarded Avr genes contribute to but are not required for pathogenicity, whereas other Avr genes are less dispensable (Keen, 1992; Long, et al, 1993). The
20 characterization of two fungal avirulence genes has also been reported. The Avr9 gene of *Cladosporium fulvum*, which confers avirulence on *C. fulvum* races that attempt to attack tomato varieties that carry the Cf-9 gene, encodes a secreted cysteine-rich peptide
25 with a final processed size of 28 amino acids but its role in compatible interactions is not clear (De Wit, 1992). The Avr4 gene of *C. fulvum* encodes a secreted peptide that is processed to a final size of amino

acids 106 (Joosten et al, 1994)

The technology for gene isolation based primarily on genetic criteria has improved dramatically in recent years, and many workers are currently attempting to clone a variety of *R* genes.

The map based cloning of the tomato *Pto* gene that confers "gene-for-gene" resistance to the bacterial speck pathogen *Pseudomonas syringae* pv tomato (*Pst*) has been reported (Martin et al, 1993). A YAC (yeast artificial chromosome) clone was identified that carried restriction fragment length polymorphism (RFLP) markers that were very tightly linked to the gene. This YAC was used to isolate homologous cDNA clones. Two of these cDNAs were fused to a strong promoter, and after transformation of a disease sensitive tomato variety, one of these gene fusions was shown to confer resistance to *Pst* strains that carry the corresponding avirulence gene, *AvrPto*. These two cDNAs show homology to each other. Indeed, the *Pto* cDNA probe reveals a small gene family of at least six members, 5 of which can be found on the YAC from which *Pto* was isolated, and which thus comprise exactly the kind of local multigene family inferred from genetic analysis of other *R* gene loci.

The *Pto* gene cDNA sequence is puzzling for proponents of the simple elicitor/receptor model. It reveals unambiguous homology to serine/threonine kinases, consistent with a role in signal

transduction. Intriguingly, there is strong homology to the kinases associated with self incompatibility in Brassicas, which carry out an analogous role, in that they are required to prevent the growth of

5 genotypically defined incompatible pollen tubes.

However, in contrast to the Brassica SRK kinase (Stein et al, 1991), the *Pto* gene appears to code for little more than the kinase catalytic domain and a potential N-terminal myristoylation site that could promote

10 association with membranes. It would be surprising if such a gene product could act alone to accomplish the specific recognition required to initiate the defence response only when the *AvrPto* gene is detected in invading microorganisms. The race-specific elicitor

15 molecule made by *Pst* strains that carry *AvrPto* is still unknown and needs to be characterized before possible recognition of this molecule by the *Pto* gene product can be investigated.

Since the isolation of the *Pto* gene a number of

20 other resistance genes have been isolated. The isolation of the tobacco mosaic resistance gene *N* from tobacco was reported by Whitham et al (1994). The isolation of the flax rust resistance gene *L6* from flax was reported by Lawrence et al (1995). The

25 isolation of two *Arabidopsis thaliana* genes for resistance to *Pseudomonas syringae* has been reported. The isolation of *RPS2* was reported by Bent et al (1994) and by Mindrinos et al (1994) and the isolation

of *RPM1* was reported by Grant et al (1995). These genes probably encode cytoplasmic proteins that carry a nucleotide binding site (NBS) and a leucine-rich repeat (LRR). The ligands with which they interact are uncharacterised and it is not known what other plant proteins they interact with to accomplish the defence response. Our own laboratory has reported the isolation of the tomato *Cf-9* gene which confers resistance against the fungus *Cladosporium fulvum*. This is disclosed in WO95/18230 and has been reported in Jones et al (1994). We have also cloned the tomato *Cf-2* gene, which confers resistance against *Cladosporium fulvum*; this is disclosed in an International patent application filed by us on 1 April 1996 claiming priority from GB 9506658.5 filed 31 March 1995 and has been reported in Dixon et al. (1996). Its structure resembles the *Cf-9* gene in that the DNA sequence predicts a protein which is predominantly extracellular, with many leucine-rich repeats and which carries a C-terminal putative membrane anchor. The *Xa21* gene of rice has also been cloned recently (Song et al., 1995). The predicted protein product of this gene exhibits an N-terminal, presumably extracellular, domain composed principally of leucine rich repeats similar to those of *Cf-9* and *Cf-2*, a predicted transmembrane domain, and a presumably cytoplasmic domain with strong similarities to serine-threonine protein kinases, particularly

that encoded by *Pto*.

The subject-matter of the present invention relates to "pathogen resistance genes" or "disease resistance genes" and uses thereof. A pathogen resistance gene (R) enables a plant to detect the presence of a pathogen expressing a corresponding avirulence gene (Avr). When the pathogen is detected, a defence response such as the hypersensitive response (HR) is activated. By such means a plant may deprive the pathogen of living cells by localised cell death at sites of attempted pathogen ingress. Other genes, including the PGIP gene of WO93/11241 (for example), are induced in the plant defence response resulting from detection of a pathogen by an R gene.

A pathogen resistance gene may be envisaged as encoding a receptor to a pathogen-derived and Avr dependent molecule. In this way it may be likened to the RADAR of a plant for detection of a pathogen. Genes involved in the defence the plant mounts to the pathogen once detected are not pathogen resistance genes. Expression of a pathogen resistance gene in a plant causes activation of a defence response in the plant. This may be upon contact of the plant with a pathogen or a corresponding elicitor molecule, though the possibility of causing activation by over-expression of the resistance gene in the absence of elicitor has been reported. The defence response may be activated locally, e.g. at a site of contact of the

plant with pathogen or elicitor molecule, or systemically. Activation of a defence response in a plant expressing a pathogen resistance gene may be caused upon contact of the plant with an appropriate, corresponding elicitor molecule. The elicitor may be contained in an extract of a pathogen such as *Peronospora parasitica*, or may be wholly or partially purified and may be wholly or partially synthetic. An elicitor molecule may be said to "correspond" if it is a suitable ligand for the R gene product to elicit activation of a defence response.

We have now isolated the *Arabidopsis RPP5* gene which confers resistance against the downy mildew fungus (*Peronospora parasitica*). We have sequenced the DNA and deduced the most likely amino acid sequence from this gene. The DNA sequence of the *Arabidopsis RPP5* genomic gene is shown in Figure 1 (SEQ ID NO. 1) and the deduced amino acid sequence is shown in Figure 2 (SEQ ID NO. 2). The prediction of the Amino acid sequence is based on the identification of introns by reverse transcriptase polymerase chain reaction using primers designed to the determined genomic sequence. The part of the DNA sequence that is presumed to be spliced into exons and encoding the *RPP5* polypeptide is shown in capital letters in Figure 1. Figure 4 (SEQ ID NO 5) shows a contiguous nucleotide sequence coding for the amino acid sequence of Figure 2, made by joining together the exons of the

sequence of Figure 1.

As described in more detail below, the *Arabidopsis RPP5* gene was isolated by map-based cloning. In this technique the locus that confers resistance is mapped at high resolution relative to restriction fragment length polymorphism (RFLP) markers that are linked to the resistance gene. We identified a marker that appeared to be absolutely linked to the resistance gene and used probes corresponding to this marker to isolate binary vector cosmid clones from a library made with DNA of an *Arabidopsis* landrace *Landsberg erecta* that carried the *RPP5* gene. A binary vector cosmid clone designated 29L17, on transformation into disease sensitive *Arabidopsis*, conferred disease resistance. DNA sequence analysis of the cloned DNA identified a gene with leucine-rich repeats. A subclone of 29L17, designated pRPP5-1, containing 6304 bp of DNA including 1298 bp 5' to the probable initiation codon (Figure 1) and 458 bp 3' to the probable termination codon was constructed in a binary vector. The subclone was used to transform *Arabidopsis* ecotype Columbia and shown to confer disease resistance. Analysis of a fast neutron induced mutation of *Landsberg* that had become disease sensitive revealed rearrangement of the DNA structure of this gene. Taken together these data provide the necessary evidence that the sequences as shown in Figures 1 and 2 correspond to the *RPP5* gene.

According to one aspect, the present invention provides a nucleic acid isolate encoding a pathogen resistance gene, the gene being characterized in that it encodes the amino acid sequence shown in SEQ ID NO 2, or a fragment thereof, or an amino acid sequence showing a significant degree of homology thereto. N and L6 may be excluded.

For instance, embodiments of nucleic acid according to the invention, e.g. encoding a polypeptide comprising an amino acid sequence that is a mutant, derivative, allele or variant of the sequence shown in Figure 2 (as discussed further herein), may be distinguished from other pathogen resistance genes such as N, L6 by optionally having any one or more of the following features:

the encoded polypeptide has less than 30% homology with the amino acid sequence of the tobacco N protein, shown in Figure 3 and less than 25% homology with the amino acid sequence of the flax L6 protein, shown in Figure 3;

its expression does not activate said defence response upon contact of the plant with a molecule that is an elicitor of the tobacco N protein;

its expression does not activate said defence response upon contact of the plant with a molecule that is an elicitor of the flax L6 protein;

its expression does not when in a tobacco plant activate said defence response upon contact of the

tobacco plant with Tobacco Mosaic Virus;

its expression does not when in a flax plant
activate said defence response upon contact of the
flax plant with *Melampsora lini*;

5 its expression does not activate said defence
response upon contact of the plant with a molecule
that is an elicitor of the *Arabidopsis* RPS2 protein;

its expression does not activate said defence
response upon contact of the plant with a molecule
10 that is an elicitor of the *Arabidopsis* RPM1 protein;

its expression does not when in *Arabidopsis*
thaliana activate said defence response upon contact
of the plant with *Pseudomonas syringae*;

the encoded polypeptide shows less than 20%
15 homology with the amino acid sequence of the tomato
Cf-9 protein and less than 20% homology with the amino
acid sequence of a tomato Cf-2 protein;

its expression does not activate said defence
response upon contact of the plant with a molecule
20 that is an elicitor of the tomato Cf-9 protein nor
with a molecule that is an elicitor of the tomato Cf-2
protein;

its expression does not when in a tomato plant
activate said defence response upon contact of the
25 tomato plant with *Cladosporium fulvum* expressing an
Avr2 molecule nor *Cladosporium fulvum* expressing an
Avr9 molecule;

the encoded polypeptide comprises a putative

nucleotide binding site;

the encoded polypeptide is a cytoplasmic protein;

the encoded polypeptide comprises a region having
homology to the cytoplasmic domain of the *Drosophila*
5 Toll protein.

Another way of distinguishing nucleic acid
according to the present invention from other pathogen
resistance genes such as N and L6 may be for the
encoded polypeptide to comprise an N-terminal domain
10 that has greater than 60% homology with the amino acid
sequence of the N-terminal domain of RPP5 shown in
Figure 2 (encoded by exon 1 of Figure 1), and/or
comprise a nucleotide binding site domain that has
greater than 40% homology with the amino acid sequence
15 of the domain of RPP5 shown in Figure 2 encoded by
exon 2 of Figure 1, and/or comprise a domain that has
greater than 30% homology with the amino acid sequence
of the domain of RPP5 shown in Figure 2 encoded by
exon 3 of Figure 1, and/or comprise a domain that has
20 greater than 30% homology with the amino acid sequence
of the leucine-rich repeat (LRR) domain of RPP5 shown
in Figure 2 encoded by exons 4, 5 and 6 of Figure 1.

Table 2 shows % amino acid identity between
putative domains of RPP5 and N, and RPP5 and L6, as
25 encoded by exons of the genomic sequences.

The nucleic acid may comprise a sequence of
nucleotides encoding an amino acid sequence showing at
least about 60% homology, preferably at least about

70% homology, at least about 80% homology, or more preferably at least about 90% or greater homology to the amino acid sequence shown in SEQ ID NO 2.

Generally, "% amino acid homology" is used to refer to
5 % amino acid identity. High homology may be indicated by ability of complementary nucleic acid to hybridise under appropriate conditions, for instance conditions stringent enough to exclude hybridisation to sequences not encoding a pathogen resistance gene. Thus, the
10 words allele, derivative or mutant may in context be used in respect of any sequence of nucleotides capable of hybridising with any of the nucleotide sequences encoding a polypeptide comprising the relevant sequence of amino acids.

15 Most preferably the nucleic acid encodes the amino acid sequence shown in SEQ ID No 2 in which case the nucleic acid may comprise DNA with an encoding sequence shown in SEQ ID NO 1 or sufficient part to encode the desired polypeptide (eg from the initiating
20 methionine codon to the first in frame downstream stop codon of the mRNA). In one embodiment, DNA comprises a sequence of nucleotides which are the nucleotides 1966 to 6511 of SEQ ID NO 1, or a mutant, derivative or allele thereof, for instance lacking introns.
25 Figure 4 provides a contiguous sequence encoding the amino acid sequence of Figure 2.

A further aspect of the invention provides a nucleic acid isolate encoding a pathogen resistance

gene, or a fragment thereof, obtainable by screening a nucleic acid library with a probe comprising nucleotides 1966 to 6511 of SEQ ID NO 1, nucleotides complementary thereto, or a fragment, derivative, mutant or allele thereof, and isolating nucleic acid which encodes a polypeptide able to confer pathogen resistance to a plant. Suitable techniques are well known in the art. Thus, the present invention also provides a method of identifying and/or isolating nucleic acid encoding a pathogen resistance gene comprising probing candidate (or "target") nucleic acid with nucleic acid which has a sequence of nucleotides which encodes the amino acid sequence shown in Figure 2, which is complementary to an encoding sequence or which encodes a fragment of either an encoding sequence or a sequence complementary to an encoding sequence. The candidate nucleic acid (which may be, for instance, cDNA or genomic DNA) may be derived from any cell or organism which may contain or is suspected of containing nucleic acid encoding a pathogen resistance gene. A preferred nucleotide sequence appears in Figure 1. Sequences complementary to the sequence shown, and fragments thereof, may be used.

Preferred conditions for probing are those which are stringent enough for there to be a simple pattern with a small number of hybridisations identified as positive which can be investigated further. It is

well known in the art to increase stringency of hybridisation gradually until only a few positive clones remain.

Nucleic acid according to the present invention
5 may encode the amino acid sequence shown in SEQ ID NO 2 or a mutant, derivative or allele of the sequence provided. Preferred mutants, derivatives and alleles are those which retain a functional characteristic of the protein encoded by the wild-type gene, especially
10 the ability to confer pathogen resistance. Changes to a sequence, to produce a mutant or derivative, may be by one or more of insertion, deletion or substitution of one or more nucleotides in the nucleic acid, leading to the insertion, deletion or substitution of
15 one or more amino acids. Of course, changes to the nucleic acid which make no difference to the encoded amino acid sequence are included.

The nucleic acid may be DNA or RNA and may be synthetic, eg with optimised codon usage for
20 expression in a host organism of choice. Nucleic acid molecules and vectors according to the present invention may be provided isolated and/or purified from their natural environment, in substantially pure or homogeneous form, or free or substantially free of
25 nucleic acid or genes of the species of interest or origin other than the sequence encoding a polypeptide with the required function. Nucleic acid according to the present invention may comprise cDNA, RNA, genomic

DNA and may be wholly or partially synthetic. The term "isolate" encompasses all these possibilities.

Also provided by an aspect of the present invention is nucleic acid comprising a sequence of
5 nucleotides complementary to a nucleotide sequence hybridisable with any encoding sequence provided herein. Another way of looking at this would be for nucleic acid according to this aspect to be hybridisable with a nucleotide sequence complementary
10 to any encoding sequence provided herein. Of course, DNA is generally double-stranded and blotting techniques such as Southern hybridisation are often performed following separation of the strands without a distinction being drawn between which of the strands
15 is hybridising. Preferably the hybridisable nucleic acid or its complement encode a polypeptide able to confer pathogen resistance on a host, i.e. includes a pathogen resistance gene. Preferred conditions for hybridisation are familiar to those skilled in the
20 art, but are generally stringent enough for there to be positive hybridisation between the sequences of interest to the exclusion of other sequences, i.e. sequences not encoding polypeptides able to confer pathogen resistance on a host.

25 The nucleic acid may be in the form of a recombinant vector, for example a phage or cosmid vector. The nucleic acid may be under the control of an appropriate promoter and regulatory elements for

expression in a host cell, for example a plant cell.
In the case of genomic DNA, this may contain its own
promoter and regulatory elements and in the case of
cDNA this may be under the control of an appropriate
5 promoter and regulatory elements for expression in the
host cell.

Those skilled in the art are well able to
construct vectors and design protocols for recombinant
gene expression. Suitable vectors can be chosen or
10 constructed, containing appropriate regulatory
sequences, including promoter sequences, terminator
fragments, polyadenylation sequences, enhancer
sequences, marker genes and other sequences as
appropriate. For further details see, for example,
15 *Molecular Cloning: a Laboratory Manual*: 2nd edition,
Sambrook et al, 1989, Cold Spring Harbor Laboratory
Press. Many known techniques and protocols for
manipulation of nucleic acid, for example in
preparation of nucleic acid constructs, mutagenesis,
20 sequencing, introduction of DNA into cells and gene
expression, and analysis of proteins, are described in
detail in *Short Protocols in Molecular Biology*, Second
Edition, Ausubel et al. eds., John Wiley & Sons, 1992.
The disclosures of Sambrook et al. and Ausubel et al.
25 are incorporated herein by reference.

When introducing a chosen gene construct into a
cell, certain considerations must be taken into
account, well known to those skilled in the art. The

nucleic acid to be inserted may be assembled within a construct which contains effective regulatory elements which will drive transcription. There must be available a method of transporting the construct into
5 the cell. Once the construct is within the cell membrane, integration into the endogenous chromosomal material may or may not occur according to different embodiments of the invention. Finally, as far as plants are concerned the target cell type must be such
10 that cells can be regenerated into whole plants.

Plants transformed with a DNA segment containing pre-sequence may be produced by standard techniques which are already known for the genetic manipulation of plants. DNA can be transformed into plant cells
15 using any suitable technology, such as a disarmed Ti-plasmid vector carried by *Agrobacterium* exploiting its natural gene transfer ability (EP-A-270355, EP-A-0116718, NAR 12(22) 8711 - 87215 1984), particle or microprojectile bombardment (US 5100792,
20 EP-A-444882, EP-A-434616), microinjection (WO 92/09696, WO 94/00583, EP 331083, EP 175966), electroporation (EP 290395, WO 8706614) or other forms of direct DNA uptake (DE 4005152, WO 9012096, US 4684611).

Agrobacterium transformation is widely used by those
25 skilled in the art to transform dicotyledonous species. Although *Agrobacterium* has been reported to be able to transform foreign DNA into some monocotyledonous species (WO 92/14828),

microprojectile bombardment, electroporation and direct DNA uptake are preferred where *Agrobacterium* is inefficient or ineffective. Alternatively, a combination of different techniques may be employed to enhance the efficiency of the transformation process, eg. bombardment with *Agrobacterium* coated microparticles (EP-A-486234) or microprojectile bombardment to induce wounding followed by co-cultivation with *Agrobacterium* (EP-A-486233).

The particular choice of a transformation technology will be determined by its efficiency to transform certain plant species as well as the experience and preference of the person practising the invention with a particular methodology of choice. It will be apparent to the skilled person that the particular choice of a transformation system to introduce nucleic acid into plant cells is not essential to or a limitation of the invention.

The *RPP5* gene, modified versions thereof and related genes encoding a protein showing a significant degree of homology to the protein product of the *RPP5* gene, alleles, mutants and derivatives thereof, may be used to confer pathogen resistance, e.g. to downy mildews, in plants. For this purpose nucleic acid as described above may be used for the production of a transgenic plant. Such a plant may possess pathogen resistance conferred by the *RPP5* gene.

The invention thus further encompasses a host

cell transformed with a vector as disclosed,
especially a plant or a microbial cell. Thus, a host
cell, such as a plant cell, comprising nucleic acid
according to the present invention is provided. Within
5 the cell, the nucleic acid may be incorporated within
the chromosome.

A vector comprising nucleic acid according to the
present invention need not include a promoter,
particularly if the vector is to be used to introduce
10 the nucleic acid into cells for recombination into the
genome.

Also according to the invention there is provided
a plant cell having incorporated into its genome a
sequence of nucleotides as provided by the present
15 invention, under operative control of a promoter for
control of expression of the encoded polypeptide. A
further aspect of the present invention provides a
method of making such a plant cell involving
introduction of a vector comprising the sequence of
20 nucleotides into a plant cell. Such introduction may
be followed by recombination between the vector and
the plant cell genome to introduce the sequence of
nucleotides into the genome. The polypeptide encoded
by the introduced nucleic acid may then be expressed.

25 A plant which comprises a plant cell according to
the invention is also provided, along with any clone
of such a plant, seed, selfed or hybrid progeny and
descendants, and any part of any of these, such as

cuttings, seed. The invention provides any plant propagule, that is any part which may be used in reproduction or propagation, sexual or asexual, including cuttings, seed and so on.

5 The invention further provides a method comprising expression from nucleic acid encoding the amino acid sequence SEQ ID NO 2, or a mutant, allele or derivative thereof, or a significantly homologous amino acid sequence, within cells of a plant (thereby
10 producing the encoded polypeptide), following an earlier step of introduction of the nucleic acid into a cell of the plant or an ancestor thereof. Such a method may confer pathogen resistance on the plant.

15 A gene stably incorporated into the genome of a plant is passed from generation to generation to descendants of the plant, cells of which descendants may express the encoded polypeptide and so may have enhanced pathogen resistance. Pathogen resistance may be determined by assessing compatibility of a pathogen
20 such as *Peronospora parasitica* or *Bremia lactucae*.

 Sequencing of the *RPP5* gene has shown that like the *Cf-9* gene and the *Cf-2* gene it includes DNA sequence encoding leucine-rich repeat (LRR) regions and homology searching has revealed strong homologies
25 to other genes containing LRRs. As discussed in WO95/18230, and further validated in this discovery, the presence of LRRs may be characteristic of many pathogen resistance genes and the presence of LRRs can

thus be used in a method of identifying further pathogen resistance genes.

Furthermore, there are some striking homologies between *RPP5* and the tobacco mosaic virus resistance gene *N* and the flax rust resistance gene *L6*. (Figure 3). (As can be derived from Figure 3, the overall homology between *RPP5* and *N* is 33% amino acid identity, while the figure for *RPP5* and *L6* is 27%.) These homologies may also be used to identify further resistance genes, for example using oligonucleotides (e.g. a degenerate pool) designed on the basis of sequence conservation, preferably conservation of amino acid sequence. In particular, primers may be designed that amplify DNA between the regions of the gene that encode the amino acid sequence F Y D V D P (SEQ ID NO 6) of *RPP5* and *N* and where in *L6* it encodes F Y M V D P (SEQ ID NO 7), and the region I A C F F (SEQ ID NO 8) of *RPP5*, where the sequence is identical in *L6* and in *N* is I A C F L (SEQ ID NO 9).

According to a further aspect, the present invention provides a method of identifying a plant pathogen resistance gene comprising use of an oligonucleotide(s) which comprise(s) a sequence or sequences that are conserved between pathogen resistance genes such as *RPP5*, *N* and *L6* to search for new resistance genes. Thus, a method of obtaining nucleic acid comprising a pathogen resistance gene (encoding a polypeptide able to confer pathogen

resistance) is provided, comprising hybridisation of an oligonucleotide (details of which are discussed herein) or a nucleic acid molecule comprising such an oligonucleotide to target/candidate nucleic acid.

- 5 Target or candidate nucleic acid may, for example, comprise a genomic or cDNA library obtainable from an organism known to encode a pathogen resistance gene. Successful hybridisation may be identified and target/candidate nucleic acid isolated for further
10 investigation and/or use.

- Hybridisation may involve probing nucleic acid and identifying positive hybridisation under suitably stringent conditions (in accordance with known techniques) and/or use of oligonucleotides as primers
15 in a method of nucleic acid amplification, such as PCR. For probing, preferred conditions are those which are stringent enough for there to be a simple pattern with a small number of hybridisations identified as positive which can be investigated
20 further. It is well known in the art to increase stringency of hybridisation gradually until only a few positive clones remain.

- As an alternative to probing, though still employing nucleic acid hybridisation, oligonucleotides
25 designed to amplify DNA sequences may be used in PCR reactions or other methods involving amplification of nucleic acid, using routine procedures. See for instance "PCR protocols; A Guide to Methods and

Applications", Eds. Innis et al, 1990, Academic Press, New York.

Preferred amino acid sequences suitable for use in the design of probes or PCR primers are sequences conserved (completely, substantially or partly) between at least two polypeptides able to confer pathogen resistance such as those encoded by RPP5 and N and/or L6.

On the basis of amino acid sequence information oligonucleotide probes or primers may be designed, taking into account the degeneracy of the genetic code, and, where appropriate, codon usage of the organism from the candidate nucleic acid is derived. Preferred nucleotide sequences may include those comprising or having a sequence encoding amino acids (i) F Y D V D P (SEQ ID NO 6); (ii) I A C F F (SEQ ID NO 8) or a sequence complementary to these encoding sequences. Suitable fragments of these may be employed. For example, the oligonucleotide TTC/T TAC/T GAC/T GTX GAT/C CC (SEQ ID NO 10) can be derived from the amino acid sequence F Y D V D P. Such an oligonucleotide primer could be used in PCR in combination with the primer A A G/A AA G/A CA XGC T/G/A AT (SEQ ID NO 11), derived from the bottom strand of the sequence that encodes I A C F F. (All sequences given 5' to 3'; see Figure 3). X indicates A, G, C or T.

Preferably an oligonucleotide in accordance with

the invention, e.g. for use in nucleic acid amplification, has about 10 or fewer codons (e.g. 6, 7 or 8), i.e. is about 30 or fewer nucleotides in length (e.g. 18, 21 or 24).

5 Assessment of whether or not such a PCR product corresponds to resistance genes may be conducted in various ways. A PCR band from such a reaction might contain a complex mix of products. Individual products may be cloned and each one individually screened for
10 linkage to known disease resistance genes that are segregating in progeny that showed a polymorphism for this probe. Alternatively, the PCR product may be treated in a way that enables one to display the polymorphism on a denaturing polyacrylamide gel and
15 specific bands that are linked to the resistance gene may be preselected prior to cloning. Once a candidate PCR band has been cloned and shown to be linked to a known resistance gene, it may then be used to isolate cDNA clones which may be inspected for other features
20 and homologies to either *RPP5*, *N* or *L6*. It may subsequently be analysed by transformation to assess its function on introduction into a disease sensitive variety of the plant of interest. Alternatively, the PCR band or sequences derived by analysing it may be
25 used to assist plant breeders in monitoring the segregation of a useful resistance gene.

A further method of using the *RPP5* sequence to identify other resistance genes is to use computer

searches of expressed sequence tag (EST) and other DNA sequence databases to identify genes in other species that encode proteins with significant *RPP5* homology. For example, a homology score of at least 60 using one
5 of the BLAST algorithms (Altschul et al, 1990) would indicate a candidate resistance gene.

Having obtained nucleic acid using any of these approaches, a nucleic acid molecule comprising all or part of the sequence of the obtained nucleic acid may
10 be used in the production of a transgenic plant, for example in order to confer pathogen resistance on the plant.

Modifications to the above aspects and
15 embodiments and further aspects and embodiments of the present invention will be apparent to those skilled in the art. All documents cited are incorporated herein by reference.

20 Figure 1 shows the genomic DNA sequence of the *RPP5* gene (SEQ ID NO. 1). Introns are shown in this Figure in non-capitalised letters. Features: Nucleic acid sequence - Translation start at nucleotide 1966; translation stop at nucleotide 6512.

25 Figure 2 shows predicted *RPP5* protein amino acid sequence (SEQ ID NO 2).

Figure 3 shows a comparison of the predicted amino acid sequence of the *RPP5* (SEQ ID NO 2), N (SEQ

ID NO 3) and L6 (SEQ ID NO 4) genes. The protein sequences are aligned according to predicted protein domains. Figure 3 was produced using the PRETTYBOX and PileUp programs of the University of Wisconsin Genetics Computer Group Sequence Analysis Software Package Version 7.2.

Figure 4 shows a contiguous nucleotide sequence (SEQ ID NO 5) encoding the amino acid sequence shown in Figure 2 (SEQ ID NO 2), and made by joining together the sequences of the exons of the sequence of Figure 1 (SEQ ID NO 1).

Cloning of the *Arabidopsis RPP5* gene

The *RPP5* gene was cloned using a map-based cloning strategy similar in principle to that used for the isolation of the tomato *Pto* gene, described briefly earlier.

(i) Assignment of *RPP5* gene map locations

The map location of *RPP5* on the *Arabidopsis* RFLP map has been reported earlier (Parker et al, 1993). This paper describes in detail how two landraces of *Arabidopsis*, designated *Columbia* and *Landsberg erecta*, showed a differential response to a race of *Peronospora parasitica* designated *NoCo-2*; *Landsberg erecta* is resistant, and *Columbia* is sensitive. Recombinant inbred lines (Lister and Dean, 1993) had been constructed, derived from carrying out single

seed descent on F2 seed derived from an F1 between Landsberg and Columbia, and these recombinant inbred lines were tested for resistance or sensitivity to NoCo-2. This analysis showed that the RPP5 gene lay
5 on Chromosome 4 between the RFLP markers m226 and g4539. The DNA of Landsberg and Columbia was analysed using the RAPD (randomly amplified polymorphic DNA) technique (Williams et al, 1990) and polymorphisms between Landsberg and Columbia were analysed for
10 linkage to RPP5. One polymorphism derived using the operon primer OPC18, which amplified a band in Columbia but not in Landsberg was absolutely linked to RPP5. This DNA band, of 540 bp (referred to as OPC18₅₄₀ in Parker et al., 1993) was cloned and the resulting
15 probe was designated the C18 probe.

(ii) Establishment of a physical map between marker m226 and marker g4539

The Arabidopsis genome project has as an
20 objective the establishment of a physical map of Chromosome 4, and ultimately of the entire Arabidopsis genome. The C18 probe was used to identify hybridising yeast artificial chromosome (YAC) clones. This facilitated the establishment of a physical contig
25 between 4539 and 226 incorporating other linked markers, such as g13683. The C18 RAPD band was cloned and used as a probe on Columbia and Landsberg genomic DNA. Hybridisation of this probe revealed a very

polymorphic small multi-gene family in these two genotypes. Hybridisation to recombinant inbred lines (Lister and Dean, 1993) showed that all members of this multi-gene family were absolutely linked to the resistance gene locus. Using the CAPS procedure (Konieczny and Ausubel, 1993) the individuals in an F2 population derived from selfing an F1 of a *Columbia* and *Landsberg* cross were screened for recombinants between the linked markers Ara-1 and 4539. The primers used for the Ara-1 locus were

Ara-1 5' TCG ACG ACT CTC AAG AAC CC 3'

Ara-2 5' CAC AAG CTA TAC GAT GCT CAC C 3'

This gave a 700 bp band in *Columbia* and *Landsberg* which, after digestion with Acc-1, cut *Landsberg* DNA giving a 360 bp and a 340 bp band. The primers used for the 4539 locus were

4539 F 5' GGT CAT CCG TTC CCA GGT AAA G 3'

4539 R 5' GGA CGT AGA ATC TGA GAG CTC 3'

After Hind III digestion, the *Columbia* 600 bp band remained uncut, whilst the *Landsberg* band was cut to give 480 bp and 120 bp fragments. In this way twenty-

four additional recombinants were derived in this interval. Analysis of these recombinants showed that again all members of the C18 multi-gene family co-segregated exactly with *RPP5*. Since linked multi-gene families are a characteristic of disease resistance genes (Martin et al, 1993; Jones et al, 1994; Whitham

et al, 1994) we tested the hypothesis that the C18 band might hybridise to the RPP5 gene. Cosmids were identified from a Landsberg binary vector cosmid library in the vector pCLD04541 (C. Dean, pers. com.; Bent et al, 1994) and cosmid clones that hybridised to the C18 probe were identified. Table 1 lists the hybridising clones. Each of these were used in transformation experiments with the readily transformable *Arabidopsis* landrace, No-O, which is sensitive to NoC0-2. A transformant was identified derived from transformation with cosmid 29L17, and self-progeny of this transformant segregated for resistance to *P. parasitica* NoC0-2. This demonstrated that the clone 29L17, which carries a band that hybridises to the C18 RAPD probe, carries a functional *Peronospora parasitica* resistance gene.

(iii) DNA sequence analysis of the 29L17 plant DNA insert

Cosmid DNA was prepared from 29L17, sonicated and cloned into pUC18 vector and randomly sequenced. Two hundred and forty (240) DNA sequencing reactions were performed on random clones that were identified as clones that hybridised to 29L17 insert DNA, i.e. clones that carried inserts of plant DNA. From a computer analysis of this DNA sequence data, a DNA sequence contig could be established comprising 14.3 kb of DNA. This DNA sequence was inspected for the

presence of sequences that encoded leucine-rich repeats. One such region, nucleotide 3000 to nucleotide 6138 in SEQ ID NO. 1, was found.

5 (iv) Analysis of a DNA rearrangement associated with an *RPP5* mutation

One criterion for establishing whether or not a characterised region of plant DNA corresponds to the gene of interest is to inspect whether mutations in
10 the corresponding gene, caused by ionizing radiation, are associated with DNA rearrangements in the region of interest. Fast neutron mutagenised *Landsberg* seed were screened with *Peronospora parasitica* for mutants to disease sensitivity. Three mutations were found and
15 analysed by Southern blots for perturbations or rearrangements in DNA corresponding to the gene, carrying leucine rich repeats. One mutant line, FNB387, showed an altered pattern of Southern blot hybridisation. More detailed analysis showed that the
20 perturbation consists of an insertion of 270 bp of DNA in the C-terminus of the reading frame that carries leucine-rich repeats. Sequence analysis of this region showed that an insertion of 270 bp had arisen from the duplication of several LRRs within the gene carried on
25 cosmid 29L17. This provides very strong evidence that the *RPP5* gene corresponds to the reading frame that carries leucine-rich repeats.

(v) Demonstration that a subclone of 29L17 contains
RPP5

To confirm that the gene identified by
mutagenesis is not only necessary but also sufficient
5 to confer disease resistance, a subclone of 29L17 was
constructed in binary vector SLJ7292. The subclone,
designated pRPP5-1, contained a 6304 bp DNA fragment
defined by a *Bgl*II restriction enzyme site 5' to the
gene (nucleotide 668 in SEQ ID NO. 1) and a *Pst*I
10 restriction enzyme site 3' to the gene (nucleotide
6971 in SEQ ID NO. 1). pRPP5-1 was used to transform
Arabidopsis ecotype Columbia and shown to confer
disease resistance.

15 (vi) RT-PCR analysis of the RPP5 transcript

First strand cDNA was prepared from seedling leaf
messenger RNA and PCR amplification from this cDNA was
performed using intron flanking primers. The primers
were: for intron 1, 5'-GAGTTCGCTCTATCATCTCC and
20 5'-TTATTGCATTGCAAACATCATTTG; for introns 2 and 3,
5'-AAATTGATCGTGCAAAGTCC and 5'-AAGATTTCGCATTCTTCAAGATT;
for intron 4, 5'-GAAGATGGATTGTGTATAATTCC and
5'-TCAAATTCGGGCATCCAGTG. For intron 5 a nested PCR
strategy was employed, an aliquot of the products of
25 the first amplification being used as the template for
the second. The primers used were: for the first
amplification, 5'-TGGTGACACTTCCTTCCTCG and
5'-CCAAACTTTTGCAGTTGTTG; for the second amplification

5'-TCTCAATGTGAGCGGCTGCAAGC and
5'-AACTTGAGCAACCACTGAGATCG. Cloned PCR products were
sequenced using a combination of vector-specific and
insert-specific primers. Intron sequences are shown in
lower case in SEQ ID NO. 1 (Figure 1) between the exon
sequences shown in upper case.

*(vii) Comparison of the RPP5 gene sequence with the
sequences of other resistance genes*

Comparison of the RPP5 sequence to the genes N
and L6 reveals very strong homologies throughout the
N-terminal region. These regions are highlighted in
Figure 3. They include regions involved in nucleotide
binding, designated Kinase-1a, Kinase-2, Kinase-3a.
Kinase-1a is often referred to as the P-loop. Also,
regions N-terminal to the nucleotide binding domain
show conspicuous homologies. Primers were designed
particularly to the conserved regions carrying the
amino acid sequence F Y D V D P (amino acids 104 to
109 of RPP5) and to amino acids I A C F F (437-441 of
RPP5). When degenerate oligonucleotide primers based
on amino acid sequence were used in PCR reactions,
both on Arabidopsis genomic DNA and on cDNA made from
RNA of other species, products were observed of the
size consistent with the potential to encode
resistance genes.

These primers could alone, or in combination with

other primers encoding conserved and non-conserved regions of the identified resistance genes, be used to isolate other homologous gene sequences which could include previously uncharacterized resistance genes.

Table 1:

Binary vector cosmid clones hybridising to C18

Binary vector: 04541

5 Transformed into No-o

3D23

27E2

29L17

38G10

10 42P15

Subsequently identified:

45F8

18A10

56G2

36

Table 2:

% amino acid identity between RPP5 and N; RPP5 and L6

	N exon1	N exon 2	N exon 3	N exon 4+5
5				
RPP5				
exon 1	55			
exon 2		36		
exon 3			26	
10 exon 4,5+6				26

	L6 exon 1	L6 exon 2	L6 exon 3	L6 exon 4
15				
RPP5				
exon 1	37			
exon 2		30		
exon 3			17	
exon 4,5+6				26

REFERENCES

1. Bent AF, et al., (1994). RPS2 of *Arabidopsis thaliana*: Science 265:1856.
- 5 2. De Wit PJGM (1992). Ann.Rev.Phytopathol. 30:391-418.
3. Dixon, MD, et al. (1996) Cell 84:451-459.
- 10 4. Flor HH (1971). Ann.Rev.Phytopathol. 9:275-296.
5. Gabriel DW, et al., (1990). Ann.Rev.Phytopathol. 28:365-391.
- 15 6. Grant, MR, et al. Science 269: 843-846 (1995)
7. Johal GS, et al., (1992). Science (Wash.). 258:985-987.
- 20 8. Jones DA, et al., (1994). Science 266:789-793.
9. Joosten MHAJ, et al., (1994). Nature 367:384.
10. Keen NT, (1992). Ann.Rev.Gen. 24:447-463.
- 25 11. Konieczny A, et al., (1993). Plant Journal 4:403-407.

12. Lawrence, GJ et al. Plant Cell 7: 1195-1206
(1995)
13. Lister C, et al., (1993). Plant Journal (in
5 press).
14. Long SR, et al., (1993). Cell 73:921-935.
15. Martin GB, et al., (1993). Science
10 262:1432-1436.
16. Mindrinos M, et al., (1994). Cell 78:1089-1099.
17. Parker JE, et al., (1993). Plant Journal
15 4:821-831.
18. Song W-Y, et al. (1995). Science 270: 1804-1806.
19. Stein JC, et al., (1991). Proc.Natl.Acad.Sci.USA.
20 88:8816-8820.
20. Whitham S, et al., (1994). Cell 78:1011-1115.
21. Williams JGK, et al., (1991). Nucl.Acids Res.
25 18:6531-6535.
22. Altschul, S.F., et al., (1990). J. Mol. Biol.
215:403-410.

CLAIMS

1. A nucleic acid isolate encoding a pathogen resistance gene whose expression in a plant can cause activation of a defence response in the plant,
5 comprising a sequence of nucleotides encoding a polypeptide comprising the sequence of amino acids shown in Figure 2
2. Nucleic acid according to claim 1 wherein said
10 activation is upon contact of the plant with a pathogen or corresponding elicitor molecule.
3. Nucleic acid according to claim 1 wherein the
15 sequence of nucleotides comprises an encoding sequence shown in Figure 1.
4. Nucleic acid according to claim 1 wherein the
sequence of nucleotides comprises an allele,
derivative or mutant, by way of addition, insertion,
20 deletion or substitution of one or more nucleotides,
of an encoding sequence shown in Figure 1.
5. Nucleic acid encoding a pathogen resistance gene
whose expression in a plant can cause activation of a
25 defence response in the plant, comprising a sequence
of nucleotides encoding a polypeptide, the polypeptide
comprising an amino acid sequence which comprises an
allele, derivative or mutant, by way of addition,

insertion, deletion or substitution of one or more amino acids, of the amino acid sequence shown in Figure 2;

with the proviso that the encoded polypeptide has at least about 60% homology with the amino acid sequence shown in Figure 2.

6. Nucleic acid encoding a pathogen resistance gene whose expression in a plant can cause activation of a defence response in the plant, comprising a sequence of nucleotides encoding a polypeptide, the polypeptide comprising an amino acid sequence which comprises an allele, derivative or mutant, by way of addition, insertion, deletion or substitution of one or more amino acids, of the amino acid sequence shown in Figure 2;

with the proviso that expression of the nucleic acid can cause said activation of a defence response upon contact of the plant with an Oomycete fungus, such as *Peronospora parasitica*, or an extract thereof.

7. Nucleic acid according to claim 5 or claim 6 wherein said activation is upon contact of the plant with a pathogen or corresponding elicitor molecule.

8. Nucleic acid which is a vector comprising nucleic acid according to any one of claims 1 to 7.

9. Nucleic acid according to claim 8 further comprising regulatory sequences for expression of said polypeptide.
- 5 10. Use of nucleic acid according to any one of the precedings claims in production of a transgenic plant.
11. A host cell comprising nucleic acid according to any one of claims 1 to 9.
- 10 12. A host cell according to claim 11 which is microbial.
13. A host cell according to claim 11 which is a
15 plant cell.
14. A plant or any part thereof comprising a cell according to claim 13.
- 20 15. Seed, selfed or hybrid progeny or a descendant or derivative or extract of a plant according to claim 14, or any part thereof.
16. A method which comprises introduction of nucleic
25 acid according to any one of claims 1 to 9 into a host cell.
17. A method according to claim 16 wherein the host

cell is a plant or microbial cell.

18. A method of conferring pathogen resistance on a plant, comprising expression from nucleic acid
- 5 according to any one of claims 1 to 9, within cells of the plant, following an earlier step of introduction of the nucleic acid into a cell of the plant or an ancestor thereof.
- 10 19. A method according to claim 18 wherein the nucleic acid encodes an amino acid sequence shown in Figure 2.
20. An oligonucleotide comprising a sequence encoding
- 15 an amino acid sequence conserved between RPP5 of *Arabidopsis* and another pathogen resistance genes or comprising a sequence complementary to a nucleotide sequence encoding a said amino acid sequence.
- 20 21. An oligonucleotide according to claim 20 wherein the pathogen resistance gene is *N* of tobacco or *L6* of flax.
22. An oligonucleotide according to claim 21
- 25 comprising a nucleotide sequence encoding one of the amino acid sequences:

(i)

F Y D/M V D P; and

(ii)

I A C F F/L

or comprising a nucleotide sequence complementary to a said encoding sequence.

5

23. An oligonucleotide according to claim 22 comprising a sequence selected from:

(i)

T T C/T T A C/T G A C/T G T X G A T/C C C;

10 (ii)

A A G/A A A G/A C A X G C T/G/A A T; and

(iii)

a sequence complementary to (i) or (ii).

15 24. An oligonucleotide which comprises a sequence which is a variant or derivative, by way of addition, insertion, deletion or substitution of one or more nucleotides, of the sequence of an oligonucleotide according to any one of claims 20 to 23.

20

25. A method of obtaining nucleic acid comprising a pathogen resistance gene comprising hybridisation of an oligonucleotide according to any one of claims 20 to 24, or a nucleic acid molecule comprising a said
25 oligonucleotide, to target nucleic acid.

26. A method according to claim 25 involving use of nucleic acid amplification.

27. A method according to claim 25 or claim 26 wherein the hybridisation is followed by identification of successful hybridisation and isolation of target nucleic acid.

5

28. A method wherein following the obtaining of nucleic acid using the method of any of claims 25 to 27 a nucleic acid molecule comprising all or part of the sequence of the obtained nucleic acid is used in
10 the production of a transgenic plant.

29. A method according to claim 28 wherein said nucleic acid molecule is used to confer pathogen resistance on said plant.

Figure 1

1	atgtgaccag	cacaaggaac	aacccttcag	gtgaaaagag	aagagagcct
51	ttgccatgtc	atggaagaaa	agcgctttta	gattttctgc	aagagacaat
101	gtctgttcca	attccaaacc	atgaagtatc	atccaaagct	cctacgtcta
151	tgagaaaacg	ggtagctgct	cttccaggga	aagctgagaa	ggaacttctt
201	tatctgaccc	caatgccact	gtgctctaac	ggtcggcctg	aagcagggtgc
251	agttctgggtg	taatcattga	cttttgtttt	tgtttcagag	tttaatttaa
301	accttaagaa	gagtttttct	gactttacta	ggggacgtaa	ttgagaagaa
351	agacgggtcct	tgctcaggaa	ccaaaggcct	ccgagctcca	gaggtacatc
401	aactgtaact	atagctcact	tctcttaata	cgagttaa	atgaaaatct
451	tgtgccttca	gactaaagtt	gtaggcctga	gctactcatt	agcacactct
501	tgatgggaaa	gctaattctc	tggggctggt	cttggctgaa	ttggtttggtg
551	caggtttgct	tcagatcttt	gcaccaagga	cctaagatag	acgtgtgggtc
601	tgcgggagtt	actttgttat	acctcataat	gggaaggaca	cctttcactg
651	gtgaccctga	acagtttaaga	tctgacttga	atgagtacac	catcactcgg
701	ttccactcgt	ttcttctttc	ttgccttctt	acaacgacct	tgtatttccc
751	aggaacataa	aggacattgc	acaactacga	ggcagtgaag	aattatggga
801	agtagccaag	ctgcacaacc	gtgaatcctc	tttccctaag	gtaacatctc
851	atcttaccac	tcttctgtac	tctccattca	tttatgagac	acataactt
901	gctctgttct	ttttaccgcc	agcttaaata	tcacataaaa	gggttttcat
951	tgtagcggtt	ttgtgttcta	ttgcttctac	tgcactccca	ttacagaaca
1001	tatatatctt	aataatgtaa	attgatgaca	aagtgattaa	atagatgac
1051	gtgagagatg	aaatcaggta	gagttttgtg	ttgttggttc	aggaattata
1101	cgagtcaagg	tacttgaagg	ggatggagtt	gagaaaatgg	ggcgaacgca
1151	acacaaaaag	cagagagttt	ctagacgcaa	ttccacggcc	gcttcttgaa
1201	ctcgttgata	gatgtttgat	agttaacccg	aggcgacgaa	tcagcgcaga
1251	ggatgctctc	aagcacgagt	tcttctatcc	agtacatgaa	acccttagaa
1301	accaa	atgct	cagcaa	aatcg	cagcc
1351	gctgacgcac	taagcgaaac	tttaaactaa	ttatacaatt	cttaaaaact
1401	aaaagagtaa	tttagcaaac	tagagagtta	attttcactt	tagcaaacta
1451	gagagttaat	ttaatttagc	gaactaatta	tattttcact	ttagtataca
1501	attcttagtg	ttaatttagt	attttcactt	atattatttg	aattaaaatc
1551	ctcataatcg	atatacttat	tctcctaata	catgtgcatg	tatgtattgg
1601	gaaacaagac	tttgatatta	aacaatcata	agtacattct	tacgataaaa
1651	tgtcttgtag	aaggacaact	gacacccaca	aaatatgtgt	gtttcaaaaat
1701	atctgtgtag	aggaaacgaa	tgtaagtttc	tgtctaattg	cctagaactt
1751	gaaatattat	ttctgtcttg	tacaaagact	aagacttatc	ataattaagt
1801	gacaaccaca	aaaattcaat	ctctaaaaat	atccttggtat	gtagtgtaaa
1851	aaagctttcg	aggaaagtaa	gacgaagttt	ctcctctctt	tctcacacta
1901	tgtcttgctg	atttacttct	cttaaaaatc	ttcgtctctt	ctctgagttc
1951	gctctatcat	ctcccATGGC	GGCTTCTTCT	TCTTCTGGCA	GACGGAGATA
2001	CGACGTTTTT	CCAAGCTTCA	GTGGGGTTGA	TGTTTCGCAAG	ACGTTCTCTCA
2051	GCCATCTTCT	CAAGGCTCTC	GACGGCAAAT	CAATCAATAC	ATTCATCGAT
2101	CATGGAATCG	AGAGAAGCCG	CACAATCGCC	CCTGAGCTTA	TATCGGCGAT
2151	TAGAGAAGCT	AGGATCTCAA	TCGTATCTT	CTCTAAGAAC	TATGCTTCTT
2201	CAACGTGGTG	CTTAAATGAA	TTGGTTGAGA	TCCACAAGTG	CTTTAATGAT
2251	TTAGGTCAAA	TGGTGATTCC	AGTTTCTAC	GACGTTGATC	CTTCGGAAGT
2301	TAGAAAACAG	ACCGGCGAAT	TTGGAAAGGT	CTTTGAAAAG	ACATGCGAGG
2351	TCAGCAAGGA	CAAACAACCA	GGGATCAGA	AACAAAGATG	GGTGCAAGCT
2401	CTCACAGATA	TAGCAAATAT	AGCCGGAGAG	GATCTTCTGA	ACGGgtacgt
2451	tgttatgatt	ccaatatatc	tgcttgcggt	ttcaattgtc	tcagaactat
2501	atttttgcat	agacttcggt	tcttctttta	ggggtgcttc	tttaattgaca
2551	aaattgactt	ttgttattag	GCCTAATGAA	GCGCATATGG	TTGAAAAGAT

Figure 1 (continued)

2601	ATCCAATGAT	GTTTCGAATA	AACTTATCAC	TCGGTCAAAG	TGTTTTGATG
2651	ACTTCGTCGG	AATTGAAGCT	CATATTGAGG	CAATAAAATC	AGTATTGTGC
2701	TTGGAATCCA	AGGAAGCTAG	AATGGTCGGG	ATTTGGGGAC	AGTCAGGGAT
2751	TGGTAAGAGT	ACCATCGGAA	GAGCTCTTTT	CAGTCAACTC	TCTAGCCAGT
2801	TCCACCATCG	CGCTTTCCTA	ACTTATAAAA	GCACCAGTGG	TAGTGACGTC
2851	TCTGGCATGA	AGTTGAGTTG	GCAAAAAGAG	CTTCTCTCGG	AAATCTTAGG
2901	TCAAAAGGAC	ATAAAGATAG	AGCATTTTGG	TGTGGTGGAG	CAAAGGTAA
2951	ATCACAAGAA	AGTTCTTATC	CTTCTTGATG	ATGTGGATAA	TCTAGAGTTT
3001	CTTAAGACCT	TGGTGGGAAA	AGCTGAATGG	TTTGGATCTG	GAAGCAGAAT
3051	AATTGTGATC	ACTCAAGATA	GGCAACTTCT	CAAGGCTCAT	GAGATTGACC
3101	TTGTATATGA	GGTGAAGCTG	CCATCTCAAG	GTCTTGCTCT	TAAGATGATA
3151	TCCCAATATG	CTTTTGGGAA	AGACTCTCCA	CCTGATGATT	TTAAGGAACT
3201	AGCATTTGAA	GTTGCCGAGC	TTGTCGGTAG	TCTTCCTTTG	GGTCTCAGTG
3251	TCTTGGGTTC	ATCTTTAAAA	GGAAGGGACA	AAGATGAGTG	GGTGAAGATG
3301	ATGCCTAGGC	TTCGAAATGA	TTCAGATGAT	AAAATTGAGG	AAACACTAAG
3351	AGTCGGCTAC	GATAGGTTAA	ATAAAAAAAA	TAGAGAGTTA	TTTAAGTGCA
3401	TTGCATGTTT	TTTCAATGGT	TTTAAAGTCA	GTAACGTCAA	AGAATTACTT
3451	GAAGATGATG	TTGGGCTTAC	AATGTTGGCT	GAGAAGTCCC	TCATACGTAT
3501	TACACCGGGT	GGATATATAG	AGATGCACAA	TTTGCTAGAG	AAATTGGGTA
3551	GAGAAATTGA	TCGTGCAAAG	TCCAAGGGTA	ATCCTGGAAA	ACGTCAATTT
3601	CTGACGAATT	TTGAGGATAT	TCGAGAAGTA	TTGACCGAGA	AAACTgtaag
3651	tttttcgcat	ctccttaaac	gttgtaatgc	atgactttat	atcaatataa
3701	tcgtaatttg	gggattgata	aacttaagca	attggtgccc	catgcgtaat
3751	taaaacgtag	ctttgatgtg	tcagaaaaat	aaaaagggtt	gcgattgtta
3801	agattatatt	agttttcttc	ggattttttt	tcagGGGACC	GAAACTCTTC
3851	TTGGAATACG	TTTGCCACAC	CCGGGATATC	TTACGACAAG	GTCGTTCTTA
3901	ATAGATGAAA	AATCATTCAA	AGGCATGCGT	AATCTCCAAT	ATCTAGAAAT
3951	TGGTTATTGG	TCAGATGGGG	TTCTACCTCA	GAGCCTCGTT	TATTTCCCTC
4001	GTAAACTCAA	AAGGCTATGG	TGGGATAATT	GTCCATTGAA	CGGTTTGCTT
4051	TCTAATTTTA	AGGCTGAGTA	TCTGGTTGAA	CTCAGAATGG	TGAATAGTAA
4101	GCTTGAGAAG	CTGTGGGATG	GAACTCAGgt	actaattttt	ttagtgatca
4151	attttctaaac	ataaaaaacta	aaaataaaaa	tgtttaaaat	gttcattaac
4201	gtgtgtgctc	tcttttcccc	tattttgttt	tcagCCCCTT	GGAAGTCTCA
4251	AGAAGATGGA	TTTGTATAAT	TCCTACAAAT	TGAAAGAAAT	TCCAGATCTT
4301	TCTTTAGCCA	TAAACCTCGA	GGAATTAAAT	CTTGAAGAAT	GCGAATCTTT
4351	GGAGACACTT	CCTTCCTCGA	TTCAGAATGC	CATTAAACTG	AGGGAGTTAA
4401	ATTGTTGGGG	GGGGCTATTA	ATAGATTTAA	AATCATTAGA	AGGCATGTGT
4451	AATCTCGAAT	ATCTATCAGT	TCCTAGTTGG	TCAAGTAGGG	AATGCACTCA
4501	GGGCATCGTT	TATTTCCCTC	GTAAACTCAA	AAGTGTATTG	TGGACTAATT
4551	GTCCATTGAA	GCGTTTGCTT	TCTAATTTTA	AGGCTGAGTA	TCTGGTTGAA
4601	CTCATAATGG	AGTACAGTGA	GCTTGAGAAG	CTGTGGGATG	GTAICTCAGgt
4651	actaatttcta	ttagtgataa	taaataatggt	agaaaaacta	aaaataaaaa
4701	tgttttaaaat	gttcattaac	gtgtgtgctc	tcttttcccc	tattttgtta
4751	tcagTCACTT	GGAAGTCTCA	AGGAGATGAA	TTTGAGGTAT	TCCAACAATT
4801	TAAAAGAAAT	TCCAGATCTT	TCTTTAGCCA	TAAACCTCGA	GGAATTAGAT
4851	CTTTTTGGAT	GCGTATCTTT	GGTGACACTT	CCTTCCTCGA	TTCAGAATGC
4901	CACTAAACTG	ATCTATTTAG	ATATGAGTGA	ATGCGAAAAT	CTAGAGAGTT
4951	TTCCAACCGT	TTTCAACTTG	AAATCTCTCG	AGTACCTCGA	TCTCACTGGA
5001	TGCCCGAATT	TGAGAAATTT	CCCAGCAATC	AAAATGGGAT	GTGCCTGGAC
5051	TAGATTATCT	CGAACAAGAT	TGTTTCCGGA	AGGGAGAAAT	GAGATCGTGG
5101	TAGAAGATTG	TTTCTGGAAC	AAGAATCTCC	CTGCTGGACT	AGATTATCTC
5151	GACTGCCTTA	TGAGATGTAT	GCCTTGTGAA	TTTCGCTCAG	AACAACTCAC

Figure 1 (continued)

5201	TTTTCTCAAT	GTGAGCGGCT	GCAAGCTTGA	GAAGCTATGG	GAAGGCATCC
5251	AGgtacattg	ttaatgctat	gctgattttt	gtttaccttc	tgttatataa
5301	ctaattaagt	atacccaa	ttgtttttat	ggcttgtggt	cgatccacgg
5351	ttatgtctta	catacatata	taataatggt	taattataat	tttaaacata
5401	tataggtata	aaattaaaa	gattatcatc	gataatgatt	gaagcatacc
5451	aatgtttttt	tcagTCGCTT	GGAGTCTCG	AAGAGATGGA	TCTGTCAGAA
5501	TCTGAAAACC	TGAAAGAACT	TCCAGATCTT	TCAAAGGCCA	CCAATCTGAA
5551	GCTTTTATGT	CTCAGCGGGT	GCAAAAGTTT	GGTGACACTT	CCTTCTACAA
5601	TTGGGAATCT	TCAAAATTTG	AGACGTTTGT	ACATGAACAG	ATGCACAGGG
5651	CTGGAGGTTT	TTCCGACCGA	TGTCAACTTG	TCATCTCTCG	AAACCCTCGA
5701	TCTCAGTGGT	TGCTCAAGTT	TGAGAACTTT	TCCTCTGATT	TCAACTAATA
5751	TTGTATGTCT	CTATCTGGAA	AACACCGCCA	TTGAAGAAAT	TCCAGATCTT
5801	TCAAAGGCCA	CCAAGCTCGA	GTCTTTGATA	CTCAACAAC	GCAAAAGTTT
5851	GGTGACACTT	CCTTCTACAA	TTGGGAATCT	TCAAAATTTG	AGACGTTTGT
5901	ACATGAACAG	ATGCACAGGG	CTGGAGCTTC	TTCCGACCGA	TGTCAACTTG
5951	TCATCTCTCG	AAACCCTCGA	TCTCAGTGGT	TGCTCAAGTT	TGAGAACTTT
6001	TCCTCTGATT	TCAACTAGAA	TGGAATGTCT	CTATCTAGAA	AACACCGCCA
6051	TTGAAGAAGT	TCCCTGCTGC	ATTGAGGATT	TCACGAGGCT	CACTGTACTA
6101	CGGATGTATT	GTTGCCAGAG	GTTGAAAAC	ATCTCCCCAA	ACATTTTTCAG
6151	ACTGACTAGT	CTTACGCTCG	CCGACTTTAC	AGACTGTAGA	GGTGTCATCA
6201	AGGCGTTGAG	TGATGCAACT	GTGGTAGCGA	CAATGGAAGA	TCACGTTTCT
6251	TGTGTACCAT	TATCTGAAAA	CATTGAATAT	ACATGTGAAC	GTTTCTGGGA
6301	TGCGTGTTCT	GATTATTACT	CTGATGACTT	TGAGGTAAAT	CGGAACCCAA
6351	TTAGATTGTC	AACGATGACT	GTCAACGATG	TGGAGTTTAA	GTTTTGTTGC
6401	TCCATTACGA	TCAAAGAATG	CGGTGTACGA	CTCTTGTATG	TCTATCAAGA
6451	AACAGAGCAC	AACCAACAAA	CTACGAGAAG	CAAGAAGCGG	ATGCGGGTAA
6501	GCCTTTTGCC	Ataattagag	ctgaaacttg	taaagcaatc	ttttgacttg
6551	atttggttta	taggatcaaa	ataccatagc	gacagactat	ttgatagaat
6601	cgatcgtttg	atatataatg	cagatgacat	cggggacatc	tgaagaagat
6651	atcaacttac	cctatggcca	aattgtagcg	gacacaggat	tggccgctct
6701	aaatacagag	ctttcgttag	ggcagggaga	agcatcatca	tcaacatctc
6751	tagaggggga	agctttgtgt	gttgatgatt	acatgataaa	tgaagaacaa
6801	gatgaacaaa	tacctatctt	gtatcctggt	tatggtaact	gaagcatctt
6851	tatcattctg	ttttgctctt	ttttaggata	acttgggatc	gaccattatt
6901	ataaatttat	aatgataatg	acaaaacgat	ttcatagggt	ttgacttttg
6951	acacaagcca	ttttttctgc	agatatagac	gatgatatgt	ggagatcatt

Figure 2.

1 MAASSSSGRR RYDVFPFSFG VDVRKTFLSH LLKALDGKSI NTFIDHGIER
51 SRTIAPELIS AIREARISIV IFSKNYASST WCLNELVEIH KCFNDLGQMV
101 IPVFYDVPDPS EVRKQTGEFG KVFEKTCEVS KDKQPGDQKQ RWVQALTDIA
151 NIAGEDLLNG PNEAHMVEKI SNDVSNKLIT RSKCFDDFVG IEAHIEAIKS
201 VLCLESKEAR MVGIWGQSGI GKSTIGRALF SQLSSQFHHR AFLTYKSTSG
251 SDVSGMKLSW QKELLSEILG QKDIKIEHFG VVEQRLNHKK VLILLDDVDN
301 LEFLKTLVGK AEWFGSGSRI IVITQDRQLL KAHEIDLVEY VKLPSQGLAL
351 KMISQYAFGK DSPPDDFKEL AFEVAELVGS LPLGLSVLGS SLKGRDKDEW
401 VKMMPRLRND SDDKIEETLR VGYDRLNKKN RELFKCIACF FNGFKVSNVK
451 ELLEDDVGLT MLAEKSLIRI TPGGYIEMHN LLEKLGREID RAKSKGNPGK
501 RQFLTNFEDI REVLTEKTGT ETLLGIRLPH PGYLTTRSFL IDEKSFKGMR
551 NLQYLEIGYW SDGVLPQSLV YFPRKLKRLW WDNCPKRLP SNFKAEYLVE
601 LRMVNSKLEK LWDGTQPLGS LKKMDLYNSY KLKEIPDLSL AINLEELNLE
651 ECESLETLP S IQNAIKLRE LNCWGGLLID LKSLEGMCNL EYLSVPSWSS
701 RECTQGIVYF PRKLKSVLWT NCPLKRLPSN FKAEYLEVELI MEYSELEKLW
751 DGTQSLGSLK EMNLRYSNL KEIPDLSLAI NLEELDIFGC VSLVTLPSI
801 QNATKLIYLD MSECENLESF PTVFNLKSLE YDLTGCPNL RNFP AIKMGC
851 AWTRLSRTRL FPEGRNEIVV EDCFWNKNLP AGLDYLDCLM RCMPCEFRSE
901 QLTFNLVSGC KLEKLWEGIQ SLGSLEEMDL SESENKELP DLSKATNLKL
951 LCLSGCKSLV TLPSTIGNLQ NLRRLYMNRC TGLEVLPTDV NLSSLETLDL
1001 SGCSSLRTP LISTNIVCLY LENTAIEEIP DLSKATKLES LILNNCKSLV
1051 TLPSTIGNLQ NLRRLYMNRC TGLELLPTDV NLSSLETLDL SGCSSLRTP
1101 LISTRIECLY LENTAIEEVP CCIEDFTRLT VLRMYCCQRL KNISPNI FRL
1151 TSLTLADFTD CRGVIKALSD ATVVATMEDH VSCVPLSENI EYTCERFWDA
1201 CSDYYSDDFE VNRNPIRLST MTVNDVEFKF CCSITIKECG VRLLYVYQET
1251 EHNQQTTRSK KRMRVSLLP

Figure 3

[illegible]

Figure 3 (continued)

Apps N L6	<p> U Y M N R C T G L E L F A . . Y T M E Q L 6 V N I T K E D E L E </p>	<p> L P T D V N I S V G S L E E D S </p>	<p> L E T L D L S G C S M R H . D I S A S D G E L T L D D T C S </p>	<p> S T R T F P I S S T S L T V E T G Q S E R I S E L S K </p>	<p> T R I E C L Y . . P E K I P S M F . . L Q K D T T L I </p>	<p> L E N T A I E B V P H H Q G H D S S U S V E V P S L R E B </p>	<p>1120 994 1221</p>
Apps N L6	<p> C C I E D E . . N V N L P E N W Y I P E G L A E L </p>	<p> T R L T V L R M Y C D K M L G E A V C Y K S T R I L Y L E G </p>	<p> C Q R L K N I S E N I F R L T S L T L A L I P W C D D K M S Q Q Q L G S L R N L </p>	<p> D E T D C R G V I K R M T N V L D I Q G </p>	<p> A L S D A T V U A T C K S L S V D H </p>	<p>1176 1038 1272</p>	
Apps N L6	<p> M E D H V S C V P L K L A L </p>	<p> S E N I E X T C E R . C D T E S S N R A R I T W P D Q P </p>	<p> H W D A C S D Y S V S E W D I H F F V R </p>	<p> D D E V N R N P I V P E A G L W D T S </p>	<p> E . F K F C C S I T G I R L S F S G E </p>	<p>1235 1091 1294</p>	
Apps N L6	<p> I K E C G V R L L Y N E K M Y G L R I L Y </p>	<p> K E G P E V N A L L </p>	<p> V Y Q E T Q M R E N S N E P T </p>	<p> B H N Q T T R S K B H S T G I R R T Q </p>	<p> K R M R V S L L P . Y N N R T S F Y E L </p>	<p>1269 1144 1294</p>	

Figure 4

ATGGCGGCTT CTTCTTCTTC TGGCAGACGG AGATACGACG TTTTCCAAG
CTTCAGTGGG GTTGATGTTC GCAAGACGTT CCTCAGCCAT CTTCTCAAGG
CTCTCGACGG CAAATCAATC AATACATTCA TCGATCATGG AATCGAGAGA
AGCCGCACAA TCGCCCCTGA GCTTATATCG GCGATTAGAG AAGCTAGGAT
CTCAATCGTC ATCTTCTCTA AGAACTATGC TTCTTCAACG TGGTGCTTAA
ATGAATTGGT TGAGATCCAC AAGTGCTTTA ATGATTAGG TCAAATGGTG
ATTCCAGTTT TCTACGACGT TGATCCTTCG GAAGTTAGAA AACAGACCGG
CGAATTTGGA AAGGTCTTTG AAAAGACATG CGAGGTCAGC AAGGACAAAC
AACCAGGGGA TCAGAAACAA AGATGGGTGC AAGCTCTCAC AGATATAGCA
AATATAGCCG GAGAGGATCT TCTGAACGGG CCTAATGAAG CGCATATGGT
TGAAAAGATA TCCAATGATG TTTCGAATAA ACTTATCACT CGGTCAAAGT
GTTTTGATGA CTTTCGTCGA ATTGAAGCTC ATATTGAGGC AATAAAATCA
GTATTGTGCT TGAATCCAA GGAAGCTAGA ATGGTCGGGA TTTGGGGAACA
GTCAGGGATT GGTAAGAGTA CCATCGGAAG AGCTCTTTTC AGTCAACTCT
CTAGCCAGTT CCACCATCGC GCTTTCCTAA CTTATAAAAG CACCAGTGGT
AGTGACGTCT CTGGCATGAA GTTGAGTTGG CAAAAGAGC TTCTCTCGGA
AATCTTAGGT CAAAAGGACA TAAAGATAGA GCATTTTGGT GTGGTGGAGC
AAAGGTTAAA TCACAAGAAA GTTCTTATCC TTCTTGATGA TGTGGATAAT
CTAGAGTTTC TTAAGACCTT GGTGGGAAAA GCTGAATGGT TTGGATCTGG
AAGCAGAATA ATTGTGATCA CTCAAGATAG GCAACTTCTC AAGGCTCATG
AGATTGACCT TGTATATGAG GTGAAGCTGC CATCTCAAGG TCTTGCTCTT
AAGATGATAT CCCAATATGC TTTTGGGAAA GACTCTCCAC CTGATGATTT
TAAGGAATA GCATTTGAAG TTGCCGAGCT TGTCGGTAGT CTTCTTTGG
GTCTCAGTGT CTTGGGTTCA TCTTTAAAAG GAAGGGACAA AGATGAGTGG
GTGAAGATGA TGCCTAGGCT TCGAAATGAT TCAGATGATA AAATTGAGGA
AACACTAAGA GTCGGCTACG ATAGGTTAAA TAAAAAAAT AGAGAGTTAT
TTAAGTGCAT TGCATGTTTT TTCAATGGTT TTAAAGTCAG TAACGTCAA
GAATTACTTG AAGATGATGT TGGGCTTACA ATGTTGGCTG AGAAGTCCCT
CATACGTATT ACACCGGGTG GATATATAGA GATGCACAAT TTGCTAGAGA
AATTGGGTAG AGAAATTGAT CGTGCAAAGT CCAAGGGTAA TCCTGGAAAA
CGTCAATTTT TGACGAATTT TGAGGATATT CGAGAAGTAT TGACCGAGAA
AACTGGGACC GAAACTCTTC TTGGAATACG TTTGCCACAC CCGGGATATC
TTACGACAAG GTCGTTCTTA ATAGATGAAA AATCATTCAA AGGCATGCGT
AATCTCCAAT ATCTAGAAAT TGGTTATTGG TCAGATGGGG TTCTACCTCA
GAGCCTCGTT TATTTCCCTC GTAAACTCAA AAGGCTATGG TGGGATAATT
GTCCATTGAA GCGTTTGCTT TCTAATTTTA AGGCTGAGTA TCTGGTTGAA
CTCAGAAATGG TGAATAGTAA GCTTGAGAAG CTGTGGGATG GAACTCAGCC
CCTTGGAAGT CTCAAGAAGA TGGATTTGTA TAATTCCTAC AAATTGAAAG
AAATTCCAGA TCTTTCTTTA GCCATAAACC TCGAGGAATT AAATCTTGAA
GAATGCGAAT CTTTGGAGAC ACTTCCTTCC TCGATTGAGA ATGCCATTAA
ACTGAGGGAG TTAAATTGTT GGGGGGGGCT ATTAATAGAT TTAAAATCAT
TAGAAGGCAT GTGTAATCTC GAATATCTAT CAGTTCCTAG TTGGTCAAGT
AGGGAATGCA CTCAGGGCAT CGTTTATTTT CCTCGTAAAC TCAAAGTGT
ATTGTGGACT AATTGTCCAT TGAAGCGTTT GCCTTCTAAT TTTAAGGCTG
AGTATCTGGT TGAATCATA ATGGAGTACA GTGAGCTTGA GAAGCTGTGG
GATGGTACTC AGTCACTTGG AAGTCTCAAG GAGATGAATT TGAGGTATTC
CAACAATTTA AAAGAAATTC CAGATCTTTC TTTAGCCATA AACCTCGAGG
AATTAGATCT TTTTGGATGC GTATCTTTGG TGACACTTCC TTCCTCGATT
CAGAATGCCA CTAAACTGAT CTATTTAGAT ATGAGTGAAT GCGAAAATCT
AGAGAGTTTT CCAACCGTTT TCAACTTGAA ATCTCTCGAG TACCTCGATC

TCACTGGATG	CCCGAATTTG	AGAAATTTCC	CAGCAATCAA	AATGGGATGT
GCCTGGACTA	GATTATCTCG	AACAAGATTG	TTTCCGGAAG	GGAGAAATGA
GATCGTGGTA	GAAGATTGTT	TCTGGAACAA	GAATCTCCCT	GCTGGACTAG
ATTATCTCGA	CTGCCTTATG	AGATGTATGC	CTTGTGAATT	TCGCTCAGAA
CAACTCACTT	TTCTCAATGT	GAGCGGCTGC	AAGCTTGAGA	AGCTATGGGA
AGGCATCCAG	TCGCTTGGA	GTCTCGAAGA	GATGGATCTG	TCAGAAATCTG
AAAACCTGAA	AGAACTTCCA	GATCTTTCAA	AGGCCACCAA	TCTGAAGCTT
TTATGTCTCA	GCGGGTGCAA	AAGTTTGGTG	ACACTTCCTT	CTACAATTGG
GAATCTTCAA	AATTTGAGAC	GTTTGTACAT	GAACAGATGC	ACAGGGCTGG
AGGTTCTTCC	GACCGATGTC	AACTTGTCAT	CTCTCGAAAC	CCTCGATCTC
AGTGGTTGCT	CAAGTTTGAG	AACTTTTCCT	CTGATTTCAA	CTAATATTGT
ATGTCTCTAT	CTGGAAAACA	CCGCCATTGA	AGAAATTCCA	GATCTTTCAA
AGGCCACCAA	GCTCGAGTCT	TTGATACTCA	ACAACTGCAA	AAGTTTGGTG
ACACTTCCTT	CTACAATTGG	GAATCTTCAA	AATTTGAGAC	GTTTGTACAT
GAACAGATGC	ACAGGGCTGG	AGCTTCTTCC	GACCGATGTC	AACTTGTCAT
CTCTCGAAAC	CCTCGATCTC	AGTGGTTGCT	CAAGTTTGAG	AACTTTTCCT
CTGATTTCAA	CTAGAATCGA	ATGTCTCTAT	CTAGAAAACA	CCGCCATTGA
AGAAGTTCCC	TGCTGCATTG	AGGATTTTAC	GAGGCTCACT	GTACTACGGA
TGTATTGTTG	CCAGAGGTTG	AAAAACATCT	CCCCAAACAT	TTTCAGACTG
ACTAGTCTTA	CGCTCGCCGA	CTTTACAGAC	TGTAGAGGTG	TCATCAAGGC
GTTGAGTGAT	GCAACTGTGG	TAGCGACAAT	GGAAGATCCG	ATTTCTTGTTG
TACCATTATC	TGAAAACATT	GAATATACAT	GTGAACGTTT	CTGGGATGCG
TGTTCTGATT	ATTACTCTGA	TGACTTTGAG	GTAAATCGGA	ACCCAATTAG
ATTGTCAACG	ATGACTGTCA	ACGATGTGGA	GTTTAAGTTT	TGTTGCTCCA
TTACGATCAA	AGAATGCGGT	GTACGACTCT	TGTATGTCTA	TCAAGAAACA
GAGCACAACC	AACAACTAC	GAGAAGCAAG	AAGCGGATGC	GGGTAAGCCT
TTTGCCA				

INTERNATIONAL SEARCH REPORT

Internat Application No
PCT/GB 96/00849

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/29 C12N15/82 A01N65/00 C12Q1/68 A01H5/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N A01N C12Q A01H

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	CELL, vol. 78, 23 September 1994, pages 1101-1115, XP002006906 WHITHAM, S., ET AL.: "The product of the tobacco mosaic virus resistance gene N: similarity to Toll and the interleukin-1 receptor" see page 1108; figure 5 ---	4,5, 7-14, 16-18
X	WO,A,94 29486 (SALK INST FOR BIOLOGICAL STUDI) 22 December 1994 see page 68 primer cSRL-2g9-tZ ---	20-22,24
X	EP,A,0 524 808 (HOFFMANN LA ROCHE ;UNIV NEW YORK (US)) 27 January 1993 see page 10 primer PV4 sequence ID no. 4 --- -/-	23,24

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

* document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

A document member of the same patent family

Date of the actual completion of the international search

28 August 1996

Date of mailing of the international search report

03.09.96

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Maddox, A

INTERNATIONAL SEARCH REPORT

Internat Application No

PCT/GB 96/00849

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	CA,A,2 115 291 (HOPE CITY) 26 August 1994 see page 4 ---	20-24
X	GENESEQ SEQUENCE DATABASE. ACCESSION NUMBER Q22930. 7-7-1992. , XP002006907 "HCV-Hc59 primer #502" see the whole document & WO,A,92 03458 (NEW YORK BLOOD CENT.) ---	20,21,24
X	EMBL SEQUENCE DATABASE RELEASE 42, 31-1-95. ACCESSION NO. T41662., XP002006908 "10243 Arabidopsis thaliana cDNA clone 63A2T7" see the whole document ---	5
P,X	WO,A,95 31564 (GATSBY CHARITABLE FOUNDATION ;JONES JONATHAN DALLAS GEORGE (GB); H) 23 November 1995 see sequence I.D. nos. 9 and 10 see page 44 ---	1-19
O,P, X	MOLECULAR BREEDING, vol. 1, 1995, pages 203-206, XP002006909 DE WIT, P.J.G.M.: "Cold Spring Harbor conference on 'Molecular biology of disease resistance in plants'" see page 204, left-hand column & DISCLOSURE BY JONATHAN JONES AT THE COLD SPRING HARBOR CONFERENCE HELD APRIL 9-12, 1995, ---	1-19
P,X	WO,A,95 28423 (GEN HOSPITAL CORP ;UNIV CALIFORNIA (US); US GOVERNMENT (US); COMMW) 26 October 1995 see the whole document ---	20,21, 24-29
Y	PLANT J. (1993), 4(5), 821-31 , XP002006910 PARKER, JANE E. ET AL: "Phenotypic characterization and molecular mapping of the Arabidopsis thaliana locus RPP5, determining disease resistance to Peronospora parasitica" see the whole document ---	1-19
Y	TRENDS IN GENETICS, vol. 11, no. 2, February 1995, pages 63-68, XP002006911 TANKSLEY, S.D., ET AL.: "Chromosome landing: a paradigm for map-based gene cloning in plants with large genomes" see the whole document ---	1-19

-/--

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO,A,95 05731 (CORNELL RES FOUNDATION INC) 2 March 1995 see claim 31 ---	10,18,19
A	CELL, vol. 80, 10 February 1995, pages 363-366, XP002006912 DANGL, J.L.: "Pièce de Résistance: novel classes of plant disease resistance genes" see page 363, left-hand column, last line - right-hand column ---	20-29
A	PLANT PHYSIOLOGY, vol. 101, 1993, pages 709-712, XP002006913 CORNELISSEN, B.J.C., ET LA.: "Strategies for control of fungal diseases with transgenic plants" see page 709, left-hand column, last paragraph - page 710, paragraph 1 ---	1-20
A	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 90, August 1993, WASHINGTON US, pages 7327-7331, XP002003882 ALEXANDER, D., ET AL.: "Increased tolerance to two oomycete pathogens in transgenic tobacco expressing pathogenesis-related protein 1a" see the whole document -----	1-20

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB 96/00849

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9429486	22-12-94	CA-A- 2164804 EP-A- 0707660	22-12-94 24-04-96
EP-A-0524808	27-01-93	AU-B- 645915 AU-B- 2041992 CA-A- 2074214 JP-A- 5336971 JP-B- 8000073 US-A- 5538871	27-01-94 25-02-93 24-01-93 21-12-93 10-01-96 23-07-96
CA-A-2115291	26-08-94	NONE	
WO-A-9531564	23-11-95	AU-B- 2415495 AU-B- 1321695	05-12-95 17-07-95
WO-A-9528423	26-10-95	AU-B- 2289595 AU-B- 2356595 WO-A- 9528478	10-11-95 10-11-95 26-10-95
WO-A-9505731	02-03-95	NONE	